Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.54 |
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | SELP | P16109 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495525 | 0.98 | FAAH (0.61) | FAAHDNM1CASP2LPAR1NAAA | |
| SCHEMBL5500554 | 0.98 | FAAH (0.61) | FAAHDNM1CASP2LPAR1NAAA | |
| SCHEMBL5501191 | 0.94 | FAAH (0.50) | FAAHDNM1CASP2LPAR1NAAA | |
| SCHEMBL31076315 | 0.88 | FAAH (0.53) | FAAHDNM1CASP2LPAR1NAAA | |
| SCHEMBL5500002 | 0.85 | CASP2 (0.57) | FAAHDNM1CASP2LPAR1NAAA | |
| SCHEMBL5088794 | 0.84 | ZDHHC7 (0.59) | FAAHCASP2LPAR1HSP90AA1ALDH1A1 | |
| SCHEMBL6261331 | 0.83 | FAAH (0.65) | FAAHDNM1CASP2LPAR1NAAA | |
| SCHEMBL1630120 | 0.82 | FAAH (0.73) | FAAHDNM1CASP2NAAAEPHX2 | |
| SCHEMBL12360830 | 0.81 | FAAH (0.62) | FAAHDNM1CASP2LPAR1NAAA | |
| SCHEMBL21600767 | 0.81 | FAAH (0.58) | FAAHDNM1CASP2LPAR1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1754700-A2 | Synthesis of oligoketides | Kosan Biosciences, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7022825-B2 | Polyketides and antibiotics | KOSAN BIOSCIENCES, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030096374-A1 | Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer | ASHLEY GARY (US) | 2003-05-22 | — | — | US | disclosed |
| US-20030092140-A1 | Novel polyketides and antibiotics | ASHLEY GARY (US) | 2003-05-15 | — | — | US | disclosed |
| US-6492562-B1 | INVENTION ALSO RELATES TO NOVEL INTERMEDIATES AND THE RESULTING MODIFIED POLYKETIDES AND ANTIBIOTICS. | KOSAN BIOSCIENCES, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1144375-A2 | SYNTHESIS OF OLIGOKETIDES | Kosan Biosciences (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000044717-A9 | SYNTHESIS OF OLIGOKETIDES | — | 2001-08-23 | — | — | WO | disclosed |
| WO-2000044717-A2 | SYNTHESIS OF OLIGOKETIDES | KOSAN BIOSCIENCES, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096374-A1 | Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer | COASY, KARS1, ACOT7 | FAAH 2517/4885DNM1 4376/4885CASP2 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.